Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of “Moderate Buy” by Analysts

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has been given a consensus recommendation of “Moderate Buy” by the twenty-two ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $69.75.

Several research analysts have recently weighed in on KYMR shares. B. Riley upped their price target on shares of Kymera Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a report on Friday, October 24th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $73.00 target price on shares of Kymera Therapeutics in a research note on Tuesday, November 4th. Mizuho assumed coverage on Kymera Therapeutics in a report on Tuesday, October 21st. They set an “outperform” rating and a $81.00 target price for the company. Barclays boosted their price target on Kymera Therapeutics from $60.00 to $70.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Finally, Truist Financial increased their price objective on Kymera Therapeutics from $53.00 to $68.00 and gave the stock a “buy” rating in a report on Tuesday, September 30th.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 79,220 shares of Kymera Therapeutics stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $50.00, for a total value of $3,961,000.00. Following the sale, the chief financial officer directly owned 227,409 shares in the company, valued at approximately $11,370,450. The trade was a 25.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Nello Mainolfi sold 30,000 shares of the business’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $49.00, for a total transaction of $1,470,000.00. Following the sale, the chief executive officer directly owned 660,482 shares in the company, valued at $32,363,618. This trade represents a 4.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 206,910 shares of company stock worth $11,402,648 in the last three months. 16.01% of the stock is currently owned by company insiders.

Institutional Trading of Kymera Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Neo Ivy Capital Management acquired a new position in shares of Kymera Therapeutics during the 1st quarter worth about $395,000. GSA Capital Partners LLP grew its holdings in Kymera Therapeutics by 6.8% during the first quarter. GSA Capital Partners LLP now owns 31,537 shares of the company’s stock worth $863,000 after purchasing an additional 1,997 shares during the period. Vanguard Group Inc. grew its holdings in Kymera Therapeutics by 7.0% during the first quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company’s stock worth $143,183,000 after purchasing an additional 344,080 shares during the period. Invesco Ltd. increased its position in Kymera Therapeutics by 36.9% during the first quarter. Invesco Ltd. now owns 42,075 shares of the company’s stock worth $1,152,000 after buying an additional 11,343 shares during the last quarter. Finally, Nuveen LLC bought a new stake in Kymera Therapeutics in the first quarter valued at approximately $3,920,000.

Kymera Therapeutics Trading Up 0.3%

Shares of Kymera Therapeutics stock opened at $64.31 on Wednesday. The stock’s fifty day simple moving average is $57.14 and its 200 day simple moving average is $46.77. The company has a market capitalization of $4.63 billion, a PE ratio of -17.91 and a beta of 2.32. Kymera Therapeutics has a 12 month low of $19.44 and a 12 month high of $68.46.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%.The business had revenue of $2.76 million for the quarter, compared to analyst estimates of $23.15 million. Analysts predict that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.